UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England

New HTA Route For “Low-Risk” Products Offers Rapid Patient Access

It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.

Torn piece of yellow paper with the word Psoriasis
UCB is expecting EU and UK approval for its plaque psoriasis drug • Source: Alamy

UCB S.A.’s plaque psoriasis therapy, bimekizumab, has become the first product to be cleared for use on the National Health Service in England by the health technology appraisal (HTA) body NICE via a new approach to the fast-track cost-comparison review process.

The fast-track appraisal (FTA) procedure was originally introduced in April 2017 for assessing products that offered “exceptional value for money,” for example where a cost comparison showed that they were likely to provide similar or greater benefits at similar or

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe

UK’s International Recognition Procedure: EU Dossier Faster Than US Or Canada

 

Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By 

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.